NKTX 241220 7.50P (NKTX241220P7500) Stock Options, News & Quotes

US OptionsDetailed Quotes

NKTX241220P7500

Watchlist

0.00
0.000.00%

15min DelayClose Dec 13 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Nkarta 13G Filing Shows Citadel Advisors Reported A 5.4% Stake In The Co As Of December 6, 2024
BenzingaDec 13 17:10 ET
Express News | Kenneth Griffin Reports 5.4% Passive Stake in Nkarta as of Dec 6 - SEC Filing
ReutersDec 13 17:04 ET
Nkarta Opens Enrolment, Receives Clearance for Autoimmune Diseases Therapy Trials
MT NewswiresDec 5 07:17 ET
Nkarta's Ntrust-2 Trial of NKX019 in Myasthenia Gravis Begins Enrollment
TipRanksDec 5 06:15 ET
Express News | Nkarta Inc: Clinical Data From Ntrust-1 and Ntrust-2 Planned for 2025
ReutersDec 5 06:01 ET
Express News | Nkarta Announces Ind Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
ReutersDec 5 06:01 ET

Comments

Jaguar8

Yesterday 08:10

🕛Watchlist MONDAY December 16. NFA. Trade the chart. Be kind… in progress

$Gorilla Technology (GRRR.US)$ PR: CEO will have interview with Red Chip Small Stock, Big Money show on Sat Dec 14. Reports on CEO on X that they have been selected from the shortlist for the $438M deal in SE Asia. Low float. $23.2M cash good for 12 months
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...

Jaguar8

Yesterday 07:39

This is good for MONDAY for me. NFA

$Nkarta (NKTX.US)$

Jaguar8

Yesterday 06:12

13G

$Nkarta (NKTX.US)$
Nkarta | SC 13G: Statement of acquisition of beneficial ownership by individuals-Kenneth Griffin(5.4%),Citadel Advisors LLC(4.5%), etc.

70205719

Dec 10 14:35

$Nkarta (NKTX.US)$
morning star? bottom now with big vol. buy now?

Jaguar8

Dec 5 05:09

NEWS

$Nkarta (NKTX.US)$
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in my...